Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting
Riet Hilhorst(PamGene (Netherlands)), Hans Morreau(Leiden University Medical Center)
Cited by 2
Related Papers
Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis
|BMC Cancer|2008|45
Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma
|European Journal of Endocrinology|2019|41
Metabolic reprogramming related to whole-chromosome instability in models for Hürthle cell carcinoma
|Scientific Reports|2020|19